Design, Synthesis, Evaluation and Biopharmaceutical Uses of Imatinib, Nilotinib and Their Analogues

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 22 July 2024 | Viewed by 195

Special Issue Editors


E-Mail Website
Guest Editor
Department of Chemistry, Atherothrombosis Research Centre, Laboratory of Biochemistry, University of Ioannina, 45110 Ioannina, Greece
Interests: athophysiology of atherosclerosis; platelets; thrombosis; antiatherogenic and antithrombotic effects; protein kinase inhibitors; cancer-associated thrombosis

E-Mail Website
Guest Editor
Department of Biological Applications and Technology, University of Ioannina, Ioannina 45110, Greece
Interests: supramolecular chemistry; organic sythesis; protein kinase inhibitors; molecular docking; dendrimers

E-Mail Website
Guest Editor
Department of Chemistry, University of Ioannina, GR-45110 Ioannina, Greece
Interests: organic sythesis; protein kinase inhibitors; molecular docking

Special Issue Information

Dear Colleagues,

Cancer is the leading cause of death worldwide, accounting for nearly 10 million deaths per year, as stated by the World Health Organization. Nearly one in six deaths is caused by cancer, with the most common being breast, lung, colon and rectum and prostate cancers.

In 2001, a revolutionary drug, which turned out to be very effective for the treatment of chronic myeloid leukemia (CML), was approved and released, changing the approach of cancer’s target therapy. The active substance, named Imatinib, was designed to deactivate a specific protein kinase, a fused BCR-ABL tyrosine protein kinase, terminating the cell signaling pathway that was responsible for the uncontrolled proliferation of white blood cells.

With Imatinib as the starting point, new molecules were synthesized with slight structural modifications, and they were evaluated for improved targeted anti-cancer properties. The innovative approach of blocking problematic protein kinase with low-molecular-weight molecules, usually by binding with the ATP-binding sites, led to the synthesis of a series of protein kinase inhibitors, and today, more than 65 of them have been approved or are under investigation in clinical trials as anti-cancer treatments. Among them is Nilotinib, a substance which has shown greater efficacy than Imatinib in patients with newly diagnosed Philadelphia chromosome-positive CML.

Pharmaceuticals launches a Special Issue, which focuses on state-of-the-art research works related to the following:

  • The design of new synthetic approaches of Imatinib and Nilotinib;
  • The development of their novel analogues;
  • The evaluation of their biological properties and selectivity;
  • Their biopharmaceutical uses.

We invite you to submit your original research articles for publication in this Special Issue.

Prof. Dr. Alexandros D. Tselepis
Dr. Dimitrios Alivertis
Dr. Pinelopi Voulgari
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • inhibitors
  • Imatinib
  • Nilotinib
  • protein kinases
  • target therapy

Published Papers

This special issue is now open for submission.
Back to TopTop